A Search Service for Abbreviation / Long Form

■ Abbreviation / Long Form : CR / complete hematological remission

[Related PubMed/MEDLINE]
Total Number of Papers: 64
[Entries Per Page]
 per page
Page Control
Page: of
Abbreviation:   CR  (>> Co-occurring Abbreviation)
Long Form:   complete hematological remission
 Abbreviation Variation
 Long Form Variation
 Pair(Abbreviation/Long Form) Variation
No. Year Title Co-occurring Abbreviation
1  2020 Cytoreductive treatment in patients with CALR-mutated essential thrombocythaemia: a study comparing indications and efficacy among genotypes from the Spanish Registry of Essential Thrombocythaemia. ET, HC
2  2020 Donor-derived CD19 CAR-T cell therapy of relapse of CD19-positive B-ALL post allotransplant. B-ALL, CAR-T cells, CI, CRS, EFS, GVHD, ICANS
3  2020 Insights from the Greek experience of the use of Blinatumomab in pediatric relapsed and refractory acute lymphoblastic leukemia patients. ALL, allo-HSCT, DLIs, MRD, OS, RFS
4  2020 Outpatient low toxic regimen with bortezomib in relapsed/refractory acute lymphoblastic leukemia in pediatrics and AYA patients: Single-center Mexican experience. BZ
5  2020 What is the role of a second allogeneic hematopoietic cell transplant in relapsed acute myeloid leukemia? allo-HCT, AML, GVHD, NRM, RCT
6  2019 A Rare Case of Primary Central Nervous System Lymphoma in an Adolescent Female Treated with High-Dose Methotrexate and Rituximab-Based Chemoimmunotherapy and Consolidation Whole Brain Radiotherapy. HD-MTX, MRI, PCNSL, WBRT
7  2019 Impact of Leukemia Stem Cells Phenotype Expression on Response to Induction Therapy in Acute Myeloid Leukemia Patients. FAB, LSCs
8  2019 Low-dose cyclosporine for active lupus nephritis: a dose titration approach. AR, LN
9  2019 The benefit of surveillance imaging for paediatric cerebellar pilocytic astrocytoma. iMRI, PA
10  2019 [Analysis of clinical characteristics, treatment response rate and survival of 77 myelodysplastic syndrome patients with del (5q) syndrome]. ACA, CCyR, CyR, LEN, MDS, OS
11  2018 A rare case of paediatric primary central nervous system lymphoma treated with high-dose methotrexate and rituximab-based chemoimmunotherapy and whole brain radiotherapy followed by tumour bed boost with three-dimensional conformal radiation technique. DLBCL, HD-MTX, MRI, PCNSL, WBRT
12  2018 Consolidation Radiation Therapy for Patients With Advanced Hodgkin Lymphoma in Complete Metabolic Response According to PET-CT or Gallium Imaging. CHT, CI, CMT, HL, HR, PET-CT, PFS, RT
13  2018 How much primary tumor metabolic volume reduction is required to improve outcome in stage III NSCLC after chemoradiotherapy? A single-centre experience. CRT, MS, NSCLC, PT-MV
14  2018 Measurable residual disease monitoring by NGS before allogeneic hematopoietic cell transplantation in AML. allo-HCT, AML, CIR, HR, MRD, NGS, VAF
15  2018 Role of ribavirin in the treatment of hepatitis C virus-associated mixed cryoglobulinemia with interferon-free regimens. CHC, DAAs, IFN, MC, RBV
16  2018 Sustained complete renal remission is a predictor of reduced mortality, chronic kidney disease and end-stage renal disease in lupus nephritis. CI, eGFR, ESRD, HR, LN, SDI
17  2018 Testing for minimal residual disease in adults with acute lymphoblastic leukemia in Europe: a clinician survey. ALL, MRD
18  2017 Repeated pulses of methyl-prednisolone with reduced doses of prednisone improve the outcome of class III, IV and V lupus nephritis: An observational comparative study of the Lupus-Cruces and lupus-Bordeaux cohorts. CC, LN
19  2016 Karyotype plus NPM1 mutation status defines a group of elderly patients with AML (≥60 years) who benefit from intensive post-induction consolidation therapy. AML, CCR, DFS, NPM1, SWOG
20  2016 Posttreatment FDG-PET-CT response is predictive of tumor progression and survival in anal carcinoma. CT, FDG PET-CT, OS, PFS
21  2015 A Case Report of Long-Term Survival following Hepatic Arterial Infusion of L-Folinic Acid Modulated 5-Fluorouracil Combined with Intravenous Irinotecan and Cetuximab Followed by Hepatectomy in a Patient with Initially Unresectable Colorectal Liver Metastases. HAI
22  2015 Arsenic trioxide-based therapy of relapsed acute promyelocytic leukemia: registry results from the European LeukemiaNet. OS
23  2015 Impact of CR before and after allogeneic and autologous transplantation in multiple myeloma: results from the EBMT NMAM2000 prospective trial. HR
24  2015 Total radiation dose and overall treatment time are predictive for tumor sterilization in cervical carcinoma treated with chemoradiation and pulsed-dose-rate brachytherapy. CTV, HR-CTV, RD
25  2014 Allogeneic mesenchymal stem cell transplantation for lupus nephritis patients refractory to conventional therapy. BILAG, GFR, LN, MSCs, MSCT, PR, SLEDAI
26  2014 Clofarabine/cyclophosphamide for debulking before stem cell transplantation. HSCT, pts
27  2014 Surgical treatment of neuroblastoma: twenty-three years of experience at a single institution. NB, NMYCA, OS
28  2013 Bortezomib and dexamethasone consolidation following risk-adapted melphalan and stem cell transplantation for patients with newly diagnosed light-chain amyloidosis. AL, BD, Mel, PR, SCT
29  2013 Capecitabine and temozolomide (CAPTEM) for metastatic, well-differentiated neuroendocrine cancers: The Pancreas Center at Columbia University experience. CAPTEM, NETs, PR, SD, TMZ
30  2013 Dynamic contrast-enhanced CT to assess metabolic response in patients with advanced non-small cell lung cancer and stable disease after chemotherapy or chemoradiotherapy. DCE, DCE-CT, NR, NSCLC, PET, RECIST, RER
31  2013 Significant efficacy of 2-chlorodeoxyadenosine{+/-} rituximab in the treatment of splenic marginal zone lymphoma (SMZL): extended follow-up. PR, SLVL/SMZL, SMZL
32  2012 Current status of hematopoietic cell transplantation in the treatment of systemic amyloid light-chain amyloidosis. AL, HDM
33  2012 Effect of resection following downstaging of unresectable hepatocelluar carcinoma by transcatheter arterial chemoembolization. AFP, HCC, TACE
34  2012 Minimal residual disease in acute myeloid leukemia: coming of age. AML, MRD
35  2012 Response rate and clinical outcome of HCC after first and repeated cTACE performed "on demand". cTACE
36  2011 Solitary skeletal osteosarcoma recurrence. Findings from the Cooperative Osteosarcoma Study Group. COSS, EFS, OS
37  2010 Significant efficacy of 2-CdA with or without rituximab in the treatment of splenic marginal zone lymphoma (SMZL). SMZL
38  2010 [Treatment of AL-amyloidosis--results from one clinic and review of published experience with new agents (bortezomib, thalidomide and lenalidomide) in AL-amyloidosis]. CTD, VGPR
39  2009 Early lymphocyte recovery after allogeneic hematopoietic SCT is associated with significant GVL effect in pediatric ALL but not acute myelogenous leukemia-Update study. HSCT
40  2009 The effectiveness and safety of mycophenolate mofetil in lupus nephritis. LN, MMF
41  2007 Arsenic but not all-trans retinoic acid overcomes the aberrant stem cell capacity of PML/RARalpha-positive leukemic stem cells. AML, APL, ATRA, CMR, LSC, RFS
42  2007 Long-term outcome of patients with AL amyloidosis treated with high-dose melphalan and stem-cell transplantation. HDM/SCT
43  2007 Transurethral Resection of Bladder Tumor (TUR-BT) then Concomitant Radiation and Cisplatin Followed by Adjuvant Gemcitabine and Cisplatin in Muscle Invasive Transitional Cell Carcinoma (TCC) of the Urinary Bladder. CCRT, PFS, RC, TCC, TURBT
44  2007 Usefulness of MRI volumetric evaluation in patients with squamous cell cancer of the head and neck treated with neoadjuvant chemotherapy. PR, SSCHN
45  2005 Long-term follow-up of gastric MALT lymphoma after Helicobacter pylori eradication. CCR, MALT, RD
46  2005 Long-term results of anti-Helicobacter pylori therapy in early-stage gastric high-grade transformed MALT lymphoma. CI, MALT, MALT
47  2005 Osteosarcoma relapse after combined modality therapy: an analysis of unselected patients in the Cooperative Osteosarcoma Study Group (COSS). COSS, OS
48  2005 Quantitation of minimal residual disease in acute myeloid leukemia by tryptase monitoring identifies a group of patients with a high risk of relapse. AML, BR
49  2005 Serum free light-chain responses after high-dose intravenous melphalan and autologous stem cell transplantation for AL (primary) amyloidosis. FLC, HDM/SCT, IFE
50  2005 [Acute myeloid leukemia with pulmonary manifestation]. ---
51  2004 A prospective, randomised, phase II study of horse antithymocyte globulin vs rabbit antithymocyte globulin as immune-modulating therapy in patients with low-risk myelodysplastic syndromes. GR, MDS, RA
52  2003 Predictors of long-term immunological outcome in rebounding patients on protease inhibitor-based HAART after initial successful virologic suppression: implications for timing to switch. AUC, NRTI, PI, REB, REB
53  2003 Tumor response to induction chemoradiation: influence on survival after esophagectomy. RT
54  2000 Detection of acute promyelocytic leukemia (APL) cells intermediately differentiated by all-trans retinoic acid in the cerebrospinal fluid: central nervous system involvement in APL. APL, ATRA
55  2000 Monitoring of minimal residual disease in patients with MLL-AF6-positive acute myeloid leukaemia by reverse transcriptase polymerase chain reaction. AML, BMT, FISH, RT-PCR
56  2000 Nodal T cell blast crisis in chronic myeloid leukemia. BC, CML
57  1999 Real-time RT-PCR for the detection and quantification of AML1/MTG8 fusion transcripts in t(8;21)-positive AML patients. AML
58  1998 Matched unrelated donor marrow transplantation in patients with advanced acute leukemia. AL, ALL, AML, GVHD, HLA, MUD
59  1995 Early detection of minimal residual disease by reverse transcriptase polymerase chain reaction predicts relapse in acute promyelocytic leukemia. APL, ATRA, RT-PCR
60  1995 Kinetics of minimal residual disease during induction/consolidation therapy in standard-risk adult B-lineage acute lymphoblastic leukemia. ALL, BM, CDR3, GMALL, IgH, MRD, PCR, TCR gamma
61  1995 [Rearrangement of the alpha RAR and pml genes in promyelocytic leukemia]. APL
62  1994 Expression of epidermal growth factor receptor and proliferating cell nuclear antigen predicts response of esophageal squamous cell carcinoma to chemoradiotherapy. EGFR, MR, PCNA, PR
63  1994 Metaphase fluorescence in situ hybridization (FISH) in the follow-up of 60 patients with haemopoietic malignancies. BMT, CT, FISH, metaphase-FISH
64  1992 Shedding of CD9 antigen by bone marrow cells from patients with acute lymphoblastic leukaemia. BM